Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After a Single Intravenous Dose of ARC-520 in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection, Followed by a Two-dose Open-label Cohort and Three Open-label Single-dose Cohorts in Treatment Naïve Patients, Including a Multi-dose Open-label Extension at a Single Center
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 Mar 2021
Price :
$35
*
At a glance
- Drugs ARC 520 (Primary) ; Chlorphenamine; Entecavir
- Indications Hepatitis B
- Focus Pharmacodynamics
- Sponsors Arrowhead Pharmaceuticals
- 12 Mar 2021 Results (n=8) of open-label extension cohort; assessing long-term off therapy effect on HBsAg levels and other viral parameters in CHB patients, published in the Gut
- 11 Dec 2018 According to an Arrowhead Pharmaceuticals media release, data from this study were presented at the European Association for the Study of the Liver (EASL) 2018.
- 11 Apr 2018 According to an Arrowhead Pharmaceuticals media release, clinical data will be presented at the International Liver Congress 2018 (ILC), the annual meeting of the European Association for the Study of the Liver (EASL).